FDA gives salvage therapy testing a push forward.
Pharmaceutical companies like to test their drugs in patients who are less seriously ill, so that the drugs will look good. A recent FDA meeting focused attention on the need for more trials in advanced patients, the importance of long-term safety follow-up for all patients, and how the necessary trials and monitoring could be conducted.